Brought to you by 
AxoGen nets $115.6mm in FOPO
11 May 2018
Executive Summary
AxoGen Inc. (allografts and surgical tools for peripheral nerve regeneration and repair) netted $115.6mm through the public offering of 3mm shares at $41. The company originally planned to sell 2mm shares. AxoGen will use the proceeds to support long-term tissue processing and manufacturing facilities for its products--including Avance off-the-shelf processed human nerve allograft; AxoGuard porcine submucosa extracellular matrix nerve connector; and Avive human umbilical cord soft tissue membrane--and to increase capacity.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
- Implantable Devices
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AxoGen nets $115.6mm in FOPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice